Skye Bioscience Future Growth

Future criteria checks 0/6

Skye Bioscience's earnings are forecast to decline at 36.1% per annum. EPS is expected to decline by 28.7% per annum.

Key information

-36.1%

Earnings growth rate

-28.7%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Good
Last updated	08 Nov 2024

Recent future growth updates

No updates

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11

Earnings and Revenue Growth Forecasts

NasdaqGM:SKYE - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-52	-47	-33	4
12/31/2025	N/A	-41	-21	-26	6
12/31/2024	N/A	-29	-25	-22	6
9/30/2024	N/A	-21	-22	-21	N/A
6/30/2024	N/A	-42	-20	-20	N/A
3/31/2024	N/A	-37	-15	-15	N/A
12/31/2023	N/A	-38	-14	-14	N/A
9/30/2023	N/A	-43	-15	-15	N/A
6/30/2023	N/A	-21	-13	-13	N/A
3/31/2023	N/A	-22	-14	-14	N/A
12/31/2022	N/A	-19	-13	-13	N/A
9/30/2022	N/A	-12	-10	-10	N/A
6/30/2022	N/A	-11	-9	-9	N/A
3/31/2022	N/A	-9	-8	-8	N/A
12/31/2021	N/A	-9	-7	-6	N/A
9/30/2021	N/A	-8	-6	-6	N/A
6/30/2021	N/A	-7	-7	-7	N/A
3/31/2021	N/A	-6	-6	-6	N/A
12/31/2020	N/A	-7	-6	-6	N/A
9/30/2020	N/A	0	-6	-6	N/A
6/30/2020	N/A	-4	-5	-5	N/A
3/31/2020	N/A	13	-6	-6	N/A
12/31/2019	N/A	1	-6	-6	N/A
9/30/2019	N/A	-10	-6	-6	N/A
6/30/2019	N/A	-7	-5	-5	N/A
3/31/2019	N/A	-26	-4	-4	N/A
12/31/2018	N/A	-19	-4	-4	N/A
9/30/2018	N/A	-14	-5	-5	N/A
6/30/2018	N/A	-12	N/A	-4	N/A
3/31/2018	N/A	-10	N/A	-4	N/A
12/31/2017	N/A	-4	N/A	-3	N/A
9/30/2017	N/A	-5	N/A	-2	N/A
6/30/2017	N/A	-5	N/A	-2	N/A
3/31/2017	N/A	-4	N/A	-3	N/A
12/31/2016	N/A	-4	N/A	-4	N/A
9/30/2016	N/A	-3	N/A	-4	N/A
6/30/2016	N/A	-3	N/A	-5	N/A
3/31/2016	N/A	-6	N/A	-4	N/A
12/31/2015	N/A	-5	N/A	-4	N/A
9/30/2015	N/A	-6	N/A	-3	N/A
6/30/2015	N/A	-6	N/A	-3	N/A
3/31/2015	N/A	-4	N/A	-3	N/A
12/31/2014	N/A	-3	N/A	-2	N/A
9/30/2014	N/A	-1	N/A	-1	N/A
6/30/2014	N/A	0	N/A	0	N/A
3/31/2014	N/A	0	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SKYE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SKYE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SKYE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SKYE's revenue is forecast to grow faster than the US market.

High Growth Revenue: SKYE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SKYE's Return on Equity is forecast to be high in 3 years time

Skye Bioscience Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor

Skye Bioscience Demonstrates Prominent Role of Peripheral Cb1 Inhibition and Achieves Significant Weight Loss with Novel Cb1-Inhibiting Antibody, Nimacimab, in Preclinical Model

Skye Bioscience, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Skye Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

High number of new directors

Skye Bioscience, Inc. announced that it has received $40 million in funding from 5AM Venture Management, LLC

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

Skye Bioscience, Inc. announced that it has received $49.99101 million in funding

Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding

Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye Bioscience, Inc. Announces Board Appointments

New major risk - Share price stability

Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors

Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma

Skye Bioscience, Inc. Appoints Rai as Member of the Nominating and Corporate Governance Committee of the Board

Skye Bioscience, Inc. Appoints Chris Twitty as Chief Scientific Officer

Skye Bioscience, Inc. (OTCPK:SKYE) completed the acquisition of Emerald Health Therapeutics, Inc. (CNSX:EMH) from Emerald Health Sciences Inc. and others.

Skye Bioscience, Inc. Completes Drug Production for Phase 1 Clinical Study

Skye Bioscience, Inc. Updates Phase 1 Timeline

Skye Bioscience, Inc. Announces Resignation of Jim Heppell as A Member of Board of Directors, Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee

Skye Bioscience, Inc. (OTCPK:SKYE) entered into a definitive agreement to acquire Emerald Health Therapeutics, Inc. (CNSX:EMH) for CAD 21.7 million.

Skye Bioscience, Inc. Reports Positive Results for SBI-100 in GLP Toxicology Study

Skye Bioscience, Inc. Reports Potential Neuroprotective Benefit of SBI-100 in Preclinical Glaucoma Model

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, Both as Combination and Single Agent, in Preclinical Study

Skye Bioscience, Inc. Announces Board Appointments

Emerald Bioscience Inc., Annual General Meeting, Jan 28, 2021

Emerald Bioscience Inc. Provides an Update on Progress across its Product Pipeline, including adjusted clinical milestones

Emerald Bioscience Inc. Announces Changes in Principal Financial Officer

Emerald Bioscience Inc. Announces Executive Changes

Emerald Bioscience Inc. has completed a Composite Units Offering in the amount of $6.939667 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies